Does ELRANATAMAB Cause Malignant neoplasm progression? 12 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Malignant neoplasm progression have been filed in association with ELRANATAMAB (Elrexfio). This represents 1.6% of all adverse event reports for ELRANATAMAB.
12
Reports of Malignant neoplasm progression with ELRANATAMAB
1.6%
of all ELRANATAMAB reports
10
Deaths
4
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ELRANATAMAB?
Of the 12 reports, 10 (83.3%) resulted in death, 4 (33.3%) required hospitalization, and 4 (33.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ELRANATAMAB. However, 12 reports have been filed with the FAERS database.
What Other Side Effects Does ELRANATAMAB Cause?
Cytokine release syndrome (131)
Immune effector cell-associated neurotoxicity syndrome (44)
Death (42)
Pyrexia (42)
Pneumonia (40)
Cytomegalovirus infection (34)
Neutropenia (30)
Covid-19 (29)
Infection (28)
Cytomegalovirus infection reactivation (24)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ELRANATAMAB Alternatives Have Lower Malignant neoplasm progression Risk?
ELRANATAMAB vs ELRANATAMAB-BCMM
ELRANATAMAB vs ELTROMBOPAG
ELRANATAMAB vs ELTROMBOPAG OLAMINE
ELRANATAMAB vs ELUXADOLINE
ELRANATAMAB vs ELVITEGRAVIR